Show All Hide All

David Sabatini

Dr. David Sabatini is a Member of the Whitehead Institute for Biomedical Research, and he is Senior Associate Member at the Broad Institute, Member of the Koch Institute for Integrative Cancer Research, and a Professor of Biology, all with the Massachusetts Institute of Technology (MIT). He is also a Howard Hughes Medical Institute Investigator. David and his lab at the Whitehead Institute study the basic mechanisms that regulate growth, the processes whereby cells and organisms accumulate mass and increase in size, as well as the role of metabolism in cancer and in the mechanisms that control the effects of dietary restriction on tumorigenesis.

William C. Hahn

Dr. William C. Hahn is a medical oncologist and Professor in the Department of Medical Oncology at the Dana-Farber Cancer Institute. Also at Dana-Faber, he co-directs the Center for Cancer Genome Discovery and serves as the Chief of the Division of Molecular and Cellular Oncology as well as Chair of the Executive Committee for Research. He is an Institute Member of the Broad Institute of MIT and Harvard. Dr. Hahn has made numerous seminal discoveries that have informed our current molecular understanding of cancer and which have defined new conceptual paradigms and formed the foundation of new translational studies.

Aviv Regev

Dr. Aviv Regev, a computational and systems biologist, is a Professor of Biology at MIT, a Howard Hughes Medical Institute Investigator, as well as Chair of the Faculty and Director of the Klarman Cell Observatory and Cell Circuits Program at the Broad Institute. Dr. Regev's research centers on understanding how complex molecular circuits function and evolve in the face of genetic and environmental changes over timeframes ranging from minutes to millions of years. She has pioneered many leading methods for the reconstruction of circuits in mammalian cells, including in single-cell genomics.

Arnold Levine

Dr. Arnold Levine is Professor Emeritus of Systems Biology at the Institute for Advanced Study in Princeton, New Jersey. He is best known for his 1979 discovery of the tumor suppressor gene p53, a molecule that inhibits tumor development. His research has fueled the design of a new generation of anti-cancer therapies that utilize inhibition of protein-protein interactions in cancer cells to initiate cell death.

Tyler Jacks

Dr. Tyler Jacks is the Director of MIT’s Koch Institute for Integrative Cancer Research and the David H. Koch Professor of Biology at MIT. He has pioneered the use of gene-targeting technology in the mouse to study cancer-associated genes and to construct mouse models of many human cancer types, including cancers of the lung, brain and ovary. His lab has made seminal contributions to the understanding of the effects of mutations of several common cancer-associated genes. This research has led to novel insights into tumor development, normal development and other cellular processes, as well as new strategies for cancer detection and treatment.

Edison T. Liu

Dr. Edison T. Liu joined The Jackson Laboratory in 2012 as President and CEO and is the director for The Jackson Laboratory Cancer Center. Previously, he served for 10 years as the founding Executive Director of the Genome Institute of Singapore and as the President of the international Human Genome Organization (HUGO). Dr. Liu’s research has focused on the functional genomics of human cancers, particularly breast cancer, uncovering new oncogenes and deciphering the dynamics of gene regulation on a genomic scale. He has authored more than 300 scientific papers and reviews and co-authored two books.

Steve Gygi

Dr. Steve Gygi received his Ph.D. from the University of Utah in the area of pharmacology and toxicology. He joined the faculty at Harvard Medical School in 2000. He is currently a Professor in the Department of Cell Biology. Dr. Gygi is a technologist who uses mass spectrometry to answer fundamental questions in both normal and abnormal biology. He specializes in instrumentation advances for global cellular protein measurements.

C. Martin Harris , MD

Dr. Harris has been a director of the Company since March 2012. He is currently Associate Vice President of the Health Enterprise and Chief Business Officer of the Dell Medical School at the University of Texas at Austin. Previously, he was CIO and Chairman of the Information Technology Division, as well as a Staff Physician at The Cleveland Clinic Foundation Department of General Internal Medicine. He also served as a Staff Physician for the Cleveland Clinic Hospital. He is currently a director of Invacare Corporation, HealthStream, Inc. and Colgate-Palmolive Company.

Cynthia Wolberger

Dr. Wolberger is a structural biologist who is on the faculty of the Johns Hopkins University School of Medicine, where she is a Professor of Biophysics and Biophysical Chemistry. Dr. Wolberger has done pioneering work on the mechanisms underlying combinatorial regulation of transcription and on ubiquitin signaling. Her current research is focused on the mechanisms by which ubiquitin plays a signaling role in transcription and in the DNA damage response.

Laura Sepp-Lorenzino

Dr. Sepp-Lorenzino joined Vertex in 2017 as VP, Head Nucleic Acid Therapies. From 2014 to 2017, she was VP, Entrepreneur-in-Residence at Alnylam, a leader in the development of RNAi Therapeutics. At Alnylam, she was responsible for the Hepatic Infectious Disease Strategic Therapeutic Area, championed Extra Hepatic siRNA Delivery internally, and via a number of collaborations, and was active in licensing and partnering. Before joining Alnylam, Dr. Sepp-Lorenzino spent 14 years at Merck & Co., having most recently served as Executive Director and Department Head, RNA Therapeutics Discovery Biology. In this role, she was responsible for identification and optimization of siRNAs and delivery vehicles, advancement of pre-clinical candidates, and development of an siRNA-conjugate platform to expand the repertoire of tissues accessible to in vivo siRNA delivery. Prior to RNAi, Laura worked in oncology drug discovery and development, having led the Cancer Research Department at Merck West Point, and having been an Assistant Lab Member and Assistant Attending Molecular Biologist at Memorial Sloan-Kettering Cancer Center. Laura received her Professional Degree in Biochemistry from the University of Buenos Aires, and her M.S. and Ph.D. in Biochemistry from New York University.

Thermo Fisher Scientific At a Glance

More than $24 billion in annual revenue and

70,000 Employees

Premier Brands

– Thermo Scientific

– Applied Biosystems

– Invitrogen

– Fisher Scientific

– Unity Lab Services

Read more

NYSE: TMO (Common Stock)Jul 22, 2019 04:01 PM

Exchange NYSE (US Dollar)NYSE

Price 291.73

Change +1.91  (+0.66%)

Volume 1,106,050

% Change

Intraday High 294.53

52 Week High 305.45

Intraday Low 289.99

52 Week Low 208.34

Today's Open 291.00

Previous Close 289.82

Minimum 20 minute delay

Investor Relations Kit

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of more than $24 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive services. For more information, please visit http://www.thermofisher.com.

The world leader in serving science